IMIDOCARB

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H20N6O
Molecular Weight	348.4017
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(NC1=CC(=CC=C1)C2=NCCN2)NC3=CC(=CC=C3)C4=NCCN4

InChI

InChIKey=SCEVFJUWLLRELN-UHFFFAOYSA-N

InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)

HIDE SMILES / InChI

Molecular Formula	C19H20N6O
Molecular Weight	348.4017
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/vet/imizol.html | http://www.adwia.com/index.php?option=com_content&view=article&id=135&Itemid=148&lang=en | https://www.vetinfo.com/treating-canine-ehrlichiosis-with-imidocarb-imizol.html

Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed: As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.

Approval Year

Targets

Primary Target	Pharmacology	Potency
Acetylcholinesterase 209 Target ID: CHEMBL4768 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742	Inhibitor 8504
Adenosine deaminase 14 Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742	Inhibitor 8504
Acetylcholinesterase 209 Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20053484	Inhibitor 8504	590.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Babesiosis 7 Sources: https://www.drugs.com/vet/imizol.html http://www.fao.org/fileadmin/user_upload/vetdrug/docs/41-11-imidocarb_dipropionate.pdf	Curative		Approved 8583	Imizol Approved Use For the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date 1997
Babesiosis 7 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500014474.pdf http://www.adwia.com/index.php?option=com_content&view=article&id=135&Itemid=148&lang=en	Curative		Approved 8583	IMIDOCARB Approved Use For treatment of babesiosis in cattle and horses Launch Date 2001

PubMed

Title	Date	PubMed
Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera.	2010-10-06	20925923
Failure of imidocarb dipropionate to eliminate Hepatozoon canis in naturally infected dogs based on parasitological and molecular evaluation methods.	2010-08-04	20444549
First case of babesiosis caused by Babesia canis canis in a dog from Norway.	2010-08-04	20378251
Haemotropic mycoplasmas: what's their real significance in cats?	2010-05	20417898
Canine babesiosis in northern Portugal and molecular characterization of vector-borne co-infections.	2010-04-08	20377861
Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli).	2009-12	20458869
Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state.	2009-10-01	19793016
Alterations in some blood coagulation parameters in naturally occurring cases of canine babesiosis.	2009-06	19584042
Ultrastructural and fluorochromatic changes of Anaplasma marginale exposed to oxytetracycline, imidocarb and enrofloxacin in short-term erythrocyte cultures.	2009-04-14	19054634
Canine babesiosis: from molecular taxonomy to control.	2009-03-26	19426443
Residue depletion of imidocarb in Swine tissue.	2009-03-25	19243130
Diagnosis and treatment of Babesia odocoilei in captive reindeer (Rangifer tarandus tarandus) and recognition of three novel host species.	2009-03	19368255
Rocky Mountain spotted fever in dogs, Brazil.	2009-03	19239764
The clinical course of babesiosis in 76 dogs infected with protozoan parasites Babesia canis canis.	2009	19459444
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture.	2008-12	20633467
Canine vector-borne diseases in Brazil.	2008-08-08	18691408
Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission.	2008-08-04	19379662
Detection of persistent Cytauxzoon felis infection by polymerase chain reaction in three asymptomatic domestic cats.	2008-07	18599854
An unusual form of canine babesiosis.	2008-03	18390102
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization.	2008-02-14	18160222
[Dogs babesiosis--still actually problem].	2008	18702315
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb.	2007-12	18277710
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs.	2007-10-21	17709209
Pharmacokinetics and bioavailability of imidocarb dipropionate in swine.	2007-08	17610411
Evidence of an acute phase response in dogs naturally infected with Babesia canis.	2007-03-31	17116368
Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa.	2007-03	17665757
Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs.	2006-09-08	16955806
Clinical manifestations of canine babesiosis in Hungary (63 cases).	2006-09	17020140
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.	2006-07	16772563
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis.	2006-06-30	16647821
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures.	2006-06	16669861
Canine babesiosis in France.	2006-05-31	16507334
Chemotherapy against babesiosis.	2006-05-31	16504402
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis.	2006-03	16613023
Effective imidocarb dipropionate therapy for Babesia shortti in falcons.	2006-02-18	16489163
Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle.	2006	17216590
[A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy].	2005-12-01	16363205
Autochthonous canine babesiosis in The Netherlands.	2005-07-15	15923085
Identification of anti-babesial activity for four ethnoveterinary plants in vitro.	2005-06-10	15893064
Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate.	2005-03	15900897
First isolation and molecular characterization of Ehrlichia canis in Spain.	2004-11-10	15482892
Detection and molecular characterization of a novel large Babesia species in a dog.	2004-10-05	15381295
[Autochthonous babesiosis in dogs in the Netherlands?].	2004-05-01	15156658
Concurrent bartonellosis and babesiosis in a dog with persistent thrombocytopenia.	2003-11-01	14621218
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.	2003-11	14665744
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages.	2003-09-19	12951065
Evaluation of certain veterinary drug residues in food.	2003	12970947
Effects of imidocarb dipropionate in cats with chronic haemobartonellosis.	2002	19750745
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992-09	1416885
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.	1988-06	3137861

Patents

Sample Use Guides

In Vivo Use Guide

Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.

Route of Administration: Other

In Vitro Use Guide

The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:46:02 GMT 2025` Edited by `admin` on `Mon Mar 31 18:46:02 GMT 2025`
Record UNII	8USS3K0VDH
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IMIZOL

Preferred Name

English

IMIDOCARB

Official Name

English

N,N'-BIS(3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENYL)UREA

Systematic Name

English

3,3'-DI-2-IMIDAZOLIN-2-YLCARBANILIDE

Common Name

English

imidocarb [INN]

Common Name

English

IMIDOCARB [MI]

Common Name

English

IMIDOCARB [MART.]

Common Name

English

UREA, N,N'-BIS(3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C277